

The Canadian Journal of Neurological Sciences

Le Journal Canadien des Sciences Neurologiques

1982 PENFIELD LECTURE

Hemispherectomy for Seizures Revisited ... *Theodore Rasmussen* 71

REVIEWS

Optic Neuritis and Multiple Sclerosis ... *G.C. Ebers and T.E. Feasby* 79

Ventricular Dilation Following Intraventricular Hemorrhage in the Premature Infant *Alan Hill* 81

ORIGINAL ARTICLES

Bromocriptine in the Long-Term Management of Advanced Parkinson's Disease *J. David Grimes and Mohammed N. Hassan* 86

Epilepsy from Cerebral Arteriovenous Malformations *Richard Leblanc, William Feindel and Roméo Ethier* 91

Febrile Seizures in Epileptic Chicks: The effects of Phenobarbital, Phenytoin and Valproate *D.D. Johnson, K.D.A. Crawford and R.D. Crawford* 96

Life Effects of Narcolepsy: Relationships to Geographic Origin (North American, Asian or European) and Other Patient and Illness Variables *Roger Broughton, Quais Ghanem, Yasuo Hishikawa, Yoshiro Sugita, Sonia Nevsimalova and Bedrich Roth* 100

The Murine Ependyoblastoma: Growth Pattern and Survival in C57B1/6J Mice *Paul J. Muller, Kyu H. Shin and Doo H. Shin* 105

Brain Swelling and Ventricle Size *R.T. Ross* 110

Sensorineural Deafness in Early Acquired Syphilis *Philippe Saltiel, Calvin A. Melmed and David Portnoy* 114

Neurology and Neurosurgery in Nepal *Robert G. Lee and Dinesh N. Gongal* 117

SPECIAL FEATURE

University of Toronto Combined Neurosciences Rounds — Rhabdomyosarcoma of the Head and Neck in Children *R.P. Humphreys, D. McGreal, C.R. Fitz, L.E. Becker and M.A. Gribbin* 119

XVIII CANADIAN CONGRESS OF NEUROLOGICAL SCIENCES — Program and Abstracts 126

NOTES AND ANNOUNCEMENTS 157



**XVIII Canadian Congress of Neurological Sciences
St. John's, Newfoundland**

June 22-June 25, 1983

The Official Journal of

The Canadian Neurological Society

The Canadian Neurosurgical Society

The Canadian Society of Clinical Neurophysiologists


The Canadian Association for Child Neurology

In life-threatening head trauma, survival may be measured in milligrams.

Hexadrol* in high doses increases survival dramatically

While these studies show that even low doses of Hexadrol* will improve the patient's chance for survival, high doses given quickly are much more beneficial.

Survival rates at increasing dosages of dexamethasone in 2 separate studies




Adapted from:

1. Gobiet W et al: Intracranial Pressure III. Edited by Beks JWF et al, Berlin, Springer-Verlag, 1976 pp. 231-4.
2. Faupel G et al: Dynamics of Brain Edema. Edited by Pappus HM, Feindel W, New York, Springer-Verlag, 1976 pp. 337-43.

	Low Dose	High Dose
Gobiet	16 mg STAT 4 mg q6h	48 mg STAT 8 mg q2h (days 1&3) 4 mg q2h (days 2&4) 4 mg q4h (days 5-8)
Faupel	12 mg STAT 4 mg q6h	100 mg STAT 100 mg (after 6 h) 4 mg q6h

Hexadrol* can be given quickly in high doses

One 10 mL vial contains 100 mg — enough to initiate therapy in these life-threatening cases. Hexadrol* is already in solution. No breaking of seals or shaking is necessary. And Hexadrol* is so stable it can be stored for up to two years at room temperature.



HEXADROL*

(dexamethasone sodium phosphate injection U.S.P.)



ORGANON CANADA LTD./LTÉE,
TORONTO, ONTARIO

Trademark Registered — Organon Inc.
Registered User — Organon Canada Ltd./Ltee.

ORGANON
BMAC

PAAB

THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES

Editor

Robert G. Lee
Calgary

Associate Editor

André Barbeau
Montreal

Founding Editor

Robert T. Ross
Winnipeg

Editorial Board

Albert J. Aguayo
Montreal

Henry J.M. Barnett
London

Paul Bédard
Quebec

Henry B. Dinsdale
Kingston

Guy Geoffroy
Montreal

Alan Hudson
Toronto

Yves Lamarre
Montreal

Bernard Lemieux
Sherbrooke

William J. Logan
Toronto

Morton Low
Vancouver

Thomas P. Morley
Toronto

Thomas J. Murray
Halifax

Donald Paty
Vancouver

Sidney J. Peerless
London

Terry Picton
Ottawa

Jean Reiher
Sherbrooke

Leo P. Renaud
Montreal

Barry Rewcastle
Calgary

Matthew W. Spence
Halifax

William G. Tatton
Toronto

Bryce Weir
Edmonton

News Editor

Arthur J. Hudson
London

THE EDITORIAL BOARD wishes to publish original work in the basic and clinical neurosciences on the understanding that it has not been and will not be published elsewhere. Review articles on timely subjects will be accepted. Manuscripts must be in triplicate including illustrations. One of the copies must be the original, ribbon copy. Manuscripts should be typed double spaced, on white paper.

Papers will be accepted in French or English. All papers should be accompanied by a short résumé in both languages. The résumé translation will be done by the editorial board if requested.

Papers should be identified only by the full name of the author, or authors, and the name of the place in which the work was done.

ILLUSTRATIONS: Photographs should be unmounted on glossy paper and show magnification scale. They should be marked on the back with figure number, title of paper and name of author.

Diagrams should be in India ink and large enough to be informative after reduction.

All illustrations should be referred to as figures, numbered consecutively, not included in the body of the text and all captions should be typed on a separate piece of paper.

Colored illustrations cannot usually be accepted unless the author is prepared to assist with the cost of reproduction.

REFERENCES to authors outside the context of the sentence should read (Name, Year). i.e. "However, a recent study (Bird and Iverson, 1975) showed a decreased, etc." Authors mentioned within the context of the sentence should read Name (Year), "i.e. . . . twenty years since Ecker and Reimshender (1951) demonstrated, etc." References should be typed in alphabetical order on a separate sheet and include author's name, initials, year, title, publication, volume first and last page, i.e. Isacson, P. (1967). Myx-oviruses and autoimmunity. *Progress in Allergy*, 10, 256-292. Abbreviations should be the same as those used in *Cumulated Index Medicus*.

Textbook references should include name of text, author's name, page number, publisher and city.

REPRINTS: Fifty reprints will be supplied free if ordered when the galley proofs are returned. More may be ordered at a nominal charge. Corrections and changes in the galley proofs, apart from printer's errors may be charged to the author.

This journal is indexed by **Index**

Editorial Assistant

Lucile G. Edwards
Calgary

Medicus, Excerpta Medica and Current Contents — Clinical Practice and Life Science.

SUBSCRIPTIONS: This journal is issued four times a year. The annual rate is \$32.00 for Canada and the U.S.A. \$34.00 elsewhere. Internes, Residents, Pre- and Post-Doctoral Students, \$16.00 per annum. Single copies \$10.00 each.

ADVERTISING: Enquiries regarding advertising space and rates should be directed to LEX LTD. VANCO PUBLICATIONS, 190 Main Street, Unionville, Ontario L3R 2G9. Telephone — (416) 297-2030.

All communications, manuscripts, subscriptions, etc., should be sent to the Editor, Canadian Journal of Neurological Sciences, Faculty of Medicine, 2500 University Drive, Calgary, Alberta, Canada T2N 1N4.

COPYRIGHT © 1983 by THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. No part of this journal may be reproduced in any form without the prior permission of The Canadian Journal of Neurological Sciences. ISSN 0317-1671. Published in conjunction with The University of Calgary Press.

Printed by Lawson Graphics Ltd.,
708 Moray Street

Winnipeg, Manitoba R3J 3S9.

Mailed under second class registration number 3307. Postage paid at Winnipeg, Manitoba.

The Journal gratefully acknowledges the support of the Winnipeg Clinic Research Institute, National Research Council Canada and the Murphy Foundation of Winnipeg.

Mobile, stable and optically unique: Surgical operating microscopes of the Wild M 600 Series.

The brand-new concepts of the WILD Surgical Operating Microscopes offer decisive advantages for microsurgery.

- **See more** with the refined optical system
- **Position comfortably** with the articulated, balanced modular design
- **Work confidently** with the rugged, stable stand and the sterilisable controls
- **Expand individually** for photography, cine and TV without special modifications



The brochure on the WILD M 600 Series Surgical Operating Microscopes is available on request, and describes in detail the possibilities of this new line.



WILD M 650 Surgical Operating Microscope on MS-C floor stand, rollable

**WILD
HEERBRUGG**

Yes, I should like to know more about the WILD Series M 600 Surgical Operating Microscopes. Please send information.

Name


Address

Post to Wild Leitz Canada Ltd.
513 McNicoll Ave., Willowdale, Ont., M2H 2C9
Tel (416) 497-2460 TWX 610-492-0485





Lioresal[®]
baclofen



**Treating spasticity
right at the start**
gives him a
better start on the
tough road back.

Early intervention with Lioresal can significantly enhance successful rehabilitation, especially before major disabilities become permanent!

- Lioresal helps relieve spasticity resulting from spinal cord injury, multiple sclerosis or other spinal cord disorders.
- Lioresal acts primarily at the spinal level eliminating the problem of troublesome over sedation?
- Lioresal improves overall outlook for long term management!

Lioresal[®]

**sooner...
means a
fuller life later.**

PAAB
CCPP
G-3017

Geigy

Mississauga, Ontario
L5N 2W5

NEUROLOGY CLINICAL RESEARCH FELLOW

Addiction Research Foundation

The Clinical Institute, Addiction Research Foundation, an affiliated teaching hospital of the University of Toronto is seeking a Neurology Clinical Research Fellow to participate in neurological research projects on the neurological consequences of alcohol and drug abuse. These studies include the use of computerized EEG analysis, evoked potentials, and CT scans. Excellent biochemical and neuro-pharmacological back-up facilities are provided, in addition to a stimulating research environment. The position is available July 1, 1983.


Applicants must be eligible for educational licensure by the Ontario College of Physicians and Surgeons.

Please apply to:

Dr. Peter L. Carlen
Head, Neurology Program
Clinical Institute
Addiction Research Foundation
33 Russell Street
Toronto, Ontario
M5S 2S1



this publication
is available in
microform



Please send me additional information.

University Microfilms International

300 North Zeeb Road
Dept. P.R.
Ann Arbor, MI 48106
U.S.A.

18 Bedford Row
Dept. P.R.
London, WC1R 4EJ
England

Name _____
Institution _____
Street _____
City _____
State _____ Zip _____

Thirty years of clinical experience

:00

:15

:30

FIORINAL

in acute head pain therapy

SANDOZ

Sandoz Canada Inc., Dorval, Québec H9R 4P5

PAAB
CCPP

In the effective treatment of epilepsy, there is no substitute for experience.

The original carbamazepine, TEGRETOL[®], was first introduced by Geigy in 1969 and subsequently became the drug of choice for trigeminal neuralgia.

But this development marked only the beginning.

Geigy research soon provided the basis for approval in the treatment of psychomotor/temporal lobe epilepsy in 1973.


And in 1979, this indication was again expanded to include usage in refractory generalized tonic/clonic seizures.

This commitment to the ongoing potential of TEGRETOL does not end here: continuing research indicates that further applications are possible in the future.

While the provision of a quality pharmaceutical is a primary objective of Geigy, other services to both doctor and patient have not gone unaddressed.


Medical information, support to continuing medical education and attention to the needs of epileptic patients, their families and Associations have been important elements in the overall attention given to this disorder.

In fact, a prescription for TEGRETOL does far more in the fight against epilepsy than just control patient symptoms.



Tegretol[®]

No Substitution.
Because there is
no substitute
for experience.
Yours, or ours.



Geigy

Mississauga, Ontario
L5N 2W5

PAAB
CCPP
G-2005

(v)

Brief Prescribing Information Tegretol® No substitution.

200 mg carbamazepine

Indications and clinical use

a) *Trigeminal Neuralgia:*

Tegretol is indicated for the symptomatic relief of pain of trigeminal neuralgia only during periods of exacerbation of true or primary trigeminal neuralgia (tic douloureux). It should not be used preventively during periods of remission. In some patients, Tegretol has relieved glossopharyngeal neuralgia. For patients who fail to respond to Tegretol, or who are sensitive to the drug, recourse to other accepted measures must be considered. Tegretol is not a simple analgesic and should not be used to relieve trivial facial pains or headaches.

b) *Tegretol has been found useful:*

1. in the management of psychomotor (temporal lobe) epilepsy and,
2. as an adjunct, in some patients with secondary or partial epilepsy with complex symptomatology or secondarily generalized seizures, when administered in combination with other antiepileptic medication.
3. as an alternative medication in patients with generalized tonic-clonic seizures who are experiencing marked side effects or fail to respond to other anticonvulsant drugs.

Tegretol is essentially ineffective in controlling petit mal, minor motor, myoclonic and predominantly unilateral seizures, and does not prevent the generalization of epileptic discharge.

Contraindications

Tegretol should not be administered to patients with a history of hepatic disease or serious blood disorder.

Tegretol should not be administered immediately before, in conjunction with, or immediately after a monoamine oxidase inhibitor. When it seems desirable to administer Tegretol to a patient who has been receiving an MAO inhibitor, there should be as long a drug-free interval as the clinical condition allows, but in no case should this be less than 14 days. Then the dosage of Tegretol should be low initially, and increased very gradually.

Tegretol should not be administered to patients presenting atrioventricular heart block. Safe use in pregnancy has not been established. Therefore, Tegretol should not be administered during the first three months of pregnancy.

Tegretol should not be given to women of child-bearing potential unless, in the opinion of the physician, the expected benefits to the patient outweigh the possible risk to the foetus (See Reproductive Studies). Because of demonstrated toxicity in nursing animals, Tegretol should not be administered to nursing mothers.

Because of the similarity of chemical structure, Tegretol should not be administered to patients with known hypersensitivity to any of the tricyclic compounds, such as amitriptyline, trimipramine, imipramine, or their analogues or metabolites.

Warnings

Although reported infrequently, serious adverse effects have been observed during the use of Tegretol. Agranulocytosis and aplastic anemia have occurred in a few instances with a fatal outcome. Leucopenia, thrombocytopenia and hepatocellular and cholestatic jaundice have also been reported. It is, therefore, important that Tegretol should be used carefully and close clinical and frequent laboratory supervision should be maintained throughout treatment in order to detect as early as possible signs and symptoms of a possible blood dyscrasia.

Long-term toxicity studies in rats indicated a potential carcinogenic risk. Therefore, the possible risk of drug use must be weighed against the potential benefits before prescribing carbamazepine to individual patients.

Precautions

Monitoring of Haematological and Other Adverse

Reactions: Complete blood studies, including platelet counts, and evaluation of hepatic and renal function and urinalysis should be carried out before treatment is instituted. Careful clinical and laboratory supervision should be maintained throughout treatment, including frequent performance of complete blood counts, in order to detect any early signs or symptoms of blood dyscrasia. Should any signs or symptoms or abnormal laboratory findings suggestive of blood dyscrasia or liver disorder occur, Tegretol should be immediately discontinued until the case is carefully reassessed.

Urinary Retention and Increased Intraocular Pressure: Because of its anticholinergic action, Tegretol should be given cautiously, if at all, to patients with increased intraocular pressure or urinary retention. Such patients should be followed closely while taking the drug.

Occurrence of Behavioural Disorders: Because it is closely related to the other tricyclic drugs, there is some possibility that Tegretol might activate a latent psychosis, or, in elderly patients, produce agitation or confusion, especially when combined with other drugs. Caution should also be exercised in alcoholics.

Use in Patients with Cardiovascular Disorders: Tegretol should be used cautiously in patients with a history of coronary artery disease, organic heart disease, or congestive failure. If a defective conductive system is suspected, an E.K.G. should be performed before administering Tegretol, in order to exclude patients with atrioventricular block.

Use in Patients taking Oral Contraceptives: In women under treatment with Tegretol, the reliability of oral contraceptives may be adversely affected; such patients should accordingly be advised to use some alternative, non-hormonal method of contraception.

Driving and Operating Hazardous Machinery: Because dizziness and drowsiness are possible side effects of Tegretol, patients should be warned about the possible hazards of operating machinery or driving automobiles.

Adverse Reactions

The reactions which have been most frequently reported with Tegretol are drowsiness, unsteadiness on the feet, vertigo, dizziness, gastrointestinal disturbances, and nausea. These reactions usually occur only during the initial phase of therapy. They have rarely necessitated discontinuing Tegretol therapy, and can be minimized by initiating treatment at a low dosage.

The more serious adverse reactions observed are the haematologic, hepatic, cardiovascular and dermatologic reactions, which require discontinuation of therapy.

The following adverse reactions have been reported:

Haematological reactions: Transitory leucopenia, eosinophilia, leucocytosis, thrombocytopenic purpura, agranulocytosis, macrocytic anemia and aplastic anemia. In a few instances, deaths have occurred.

Hepatic disturbances: During the long-term administration of Tegretol abnormalities in liver function tests and cholestatic or hepatocellular jaundice have been observed.

Dermatological reactions: The following reactions occurred during treatment with Tegretol: skin sensitivity reactions and rashes, erythematous rashes, pruritic eruptions, urticaria, photosensitivity, pigmentary changes, neurodermatitis and in rare cases Stevens-Johnson syndrome, exfoliative dermatitis, alopecia, diaphoresis, erythema multiforme, erythema nodosum, and aggravation of disseminated lupus erythematosus.

Neurological reactions: The reactions reported as occurring during treatment with Tegretol include vertigo, somnolence, disturbances of coordination, confusion, headache, fatigue, blurred vision, transient diplopia and oculomotor disturbances, speech disturbances, abnormal involuntary movements and increase in motor seizures. In addition, peripheral neuritis and paresthesia, depression with agitation, talkativeness,

nystagmus, and tinnitus have been reported but only very rarely. There have been some reports of paralysis and other symptoms of cerebral arterial insufficiency but no conclusive relationship to the administration of Tegretol could be established.

Cardiovascular systems: Recurrence of thrombophlebitis in patients with a prior history of thrombophlebitis, congestive heart failure, aggravation of hypertension, Stokes-Adams in patients with AV block, hypotension, syncope and collapse, edema, aggravation of coronary artery disease. Some of these complications (including myocardial infarction and arrhythmia) have been associated with other tricyclic compounds.

Genitourinary reactions: Urinary frequency, acute urinary retention, oliguria with elevated blood pressure, and impotence. Elevation of BUN, albuminuria and glycosuria also have been observed.

Digestive tract: Disturbances associated with Tegretol therapy have included nausea, vomiting, gastric or abdominal discomfort, diarrhoea, anorexia and dryness of the mouth and throat, glossitis and stomatitis.

Eyes: There is no conclusive evidence that Tegretol produces pathological changes in the cornea, lens or retina. However, it should be recognized that many phenothiazines and related drugs have been shown to cause eye changes. By analogy, periodic eye examinations, including slitlamp funduscopy and tonometry, are recommended.

Other reactions reported during treatment with Tegretol include fever and chills, lymphadenopathy, aching joints and muscles, leg cramps and conjunctivitis.

Dosage and Administration

Use in Epilepsy (see Indications): A low initial daily dosage with a gradual increase in dosage is advised. Dosage should be adjusted to the needs of the individual patient.

Adults and Children over 12 years of age: Initially, 100 to 200 mg once or twice a day depending on the severity of the case and previous therapeutic history. The initial dosage is progressively increased, until the best response is obtained, up to 600 mg daily. The usual optimal dosage is 600 mg daily, but occasionally dosage up to 800 to 1000 mg have been used for short periods. As soon as disappearance of seizures has been obtained and maintained, dosage should be reduced very gradually until a minimum effective dose is reached.

Use in trigeminal neuralgia: The initial daily dosage should be small; 200 mg, taken in two doses of 100 mg each is recommended. The total daily dosage can be increased by 200 mg per day until relief of pain is obtained. This is usually achieved at a dosage between 200 and 800 mg daily, but occasionally up to 1200 mg per day may be necessary. As soon as relief of pain has been obtained and maintained, progressive reduction in dosage should be attempted until a minimum effective dosage is reached. Because trigeminal neuralgia is characterized by periods of remission, attempts should be made to reduce or discontinue the use of Tegretol at intervals of not more than 3 months, depending upon the individual clinical course.

Prophylactic use of the drug in trigeminal neuralgia is not recommended.

Tegretol should be taken in two or three divided doses daily, with meals whenever possible.

Dosage Forms

Tegretol is available as a 200 mg white, round, flat bevelled edge single-scored tablet, engraved with Geigy signet.

Availability

Bottles of 50 and 500 tablets. Protect from heat and humidity.


Full information available on request.

Geigy


Mississauga, Ontario
L5N 2W5

PAAB
CCPP
G-2005


POLYSOMNOGRAPHIC RECORDING FOR CLINIC OR RESEARCH



MODEL 8



Onset of REM sleep. Figure 1. A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects. UCLA-BIS-DHEW.



MODEL 78

For multiple parameter recording of sleep-wake disorders in the clinical or the research setting, Grass Polygraphs and EEGs have the reliability and flexibility required.

For research applications, the Model 78 Polygraph with a wide selection of interchangeable signal conditioning preamplifiers allows recording several channels of EEG, EOG, EMG, ENG, temperature, respiration, EKG, blood gases, etc., with convenience and ease. A wide range of transducers, recording accessories, plus multiple chart speeds, *including the widely used 10 mm/sec*, provide a complete sleep-wake recording system.

For dual purpose applications where the primary interest is in clinical EEG and the secondary interest involves multiple parameter sleep studies, the Model 8 EEG is the instrument of choice.

For dependable long-term studies — rely on Grass, recording bioelectric activity since 1935.

Write for further information on a system to meet your polysomnographic recording needs.

GRASS / SINCE 1935
MEDICAL INSTRUMENTS

QUINCY, MASS. 02169 • 617/773-0002

**Some drugs
are just too important
to allow substitution**

Tegretol[®]

Carbamazepine

**The original carbamazepine
for the treatment of epilepsy.
Because there is no substitute
for experience.**

Yours or Ours.



Geigy

Mississauga, Ontario
L5N 2W5

FAAB
CCP